All In Biotech

Investigational drug · Phase 3

AOC 1044

Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for DMD, Duchenne Muscular Dystrophy, Exon 44.

Phase 3

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

3

2 still active

All registered trials

4

Any phase or sponsor naming "AOC 1044"

First trial start

2022

Nov 9, 2022

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "AOC 1044", any sponsor or status.

Conditions studied

As listed on its trial records.

  • DMD
  • Duchenne Muscular Dystrophy
  • Exon 44
  • Duchenne
  • Muscular Dystrophies
  • Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy)
  • Muscular Disorders, Atrophic
  • Muscular Disease
  • Musculoskeletal Diseases
  • Neuromuscular Diseases (NMD)

Approved drugs for the same conditions: Duchenne muscular dystrophy · Neurology · Rare and genetic disease

Largest trials

Live from ClinicalTrials.gov: studies naming "AOC 1044" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 2 on PubMed

Also in development for DMD

  • Zeleciment RostudirsenDYNE-251Phase 32 trials

    Dyne Therapeutics · Duchenne Muscular Dystrophy (DMD), Muscular Dystrophy, Duchenne, Muscular Dystrophy (DMD)

  • BrogidirsenNS-089, NCNP-02Phase 23 trials

    NS Pharma, Inc. · Duchenne Muscular Dystrophy, Exon 44, DMD

  • SAT-3247Phase 22 trials

    Satellos Bioscience, Inc. · Duchenne Muscular Dystrophy, Duchenne, DMD

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.